What the buyer wrote
CAR-T treatment called Obecel developed to treat relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (r/r B-ALL) which has recently become available to patients. The decision which treatment is most suitable applicable to a specific age group is a clinical one that would be decided by a Multi-Disciplinary Team (MDT). The product should meet strict NHS England standards for cryogenic storage and handling and RMH has such credentials.
Bid for this and lost? There is a short window in which the decision can be questioned.
Awarded to
Supplier not named£380kends
Details
- What the buyer calls it
- RMH - CAR-T Treatment
- How they are buying
- Given to one supplier, no competitionNobody else was asked, and the buyer has to be able to justify that.
- Work starts
- 1 Nov 2025
- Work ends
- 31 Oct 2026
- Where
- in London
- Kind of work
- Logistics, courier and distribution
Who the buyer named
tenders@chelwest.nhs.uk was the named contact on this notice.